Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call Transcript
Nichol L. Ochsner: Good afternoon, and thank you for joining Zevra Therapeutics, Inc.'s First Quarter 2026 Financial Results and Corporate Update Conference Call.
Zevra Therapeutics Inc. (ZVRA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 1,200,000 | $11,184,000 | 1.53% | |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.79 | 3,175 | $24,718.01 | 3,894 | 2025-09-12 | Filing | |
| $7.89 | 20,000 | $157,800.00 | 20,000 | 2025-09-12 | Filing | |
| $9.17 | 5,000 | $45,825.00 | 45,000 | 2025-08-19 | Filing | |
| $7.84 | 300 | $2,351.52 | 1,800 | 2025-03-28 | Filing | |
| $7.96 | 10,000 | $79,624.00 | 40,000 | 2025-03-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.56 | 14,625 | $125,185.61 | 387,225 | 2026-02-09 | Filing | |
| $9.18 | 3,000 | $27,548.10 | 29,590 | 2026-02-03 | Filing | |
| $9.19 | 10,500 | $96,500.25 | 62,278 | 2026-02-03 | Filing | |
| $8.82 | 1,750 | $15,442.00 | 20,924 | 2026-01-30 | Filing | |
| $8.83 | 4,080 | $36,009.67 | 49,919 | 2026-01-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,469,328 | $23,014,137 | 0% | |
| 2. | 1,163,090 | $10,839,999 | 0% | |
| 3. | 651,148 | $6,068,699 | 2.47% | |
| 4. | 554,802 | $5,167,884 | 0% | |
| 5. | 466,303 | $4,345,944 | 0% |
News See All
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra's Third Quarter 2025 Financial Results and Corporate Update Conference Call.
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is one of the best affordable biotech stocks to invest in now. On September 4, Zevra Therapeutics, Inc.
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra's Second Quarter 2025 Financial Results and Corporate Update Conference Call.
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT
Its fiscal Q1 2025 results, reported on May 15, showed positive operations, with net revenue reaching $20.4 million, driven by product net revenue of $17.2 million.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and thank you for joining Zevra's First Quarter 2025 Financial Results and Corporate Update Conference Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2024 Earnings Call Transcript
Operator: Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call.
Hedge Fund Resource Center